|
Video: What is a Stock Split?
|
|
ImmunoGen is a clinical-stage biotechnology company focused on developing the antibody-drug conjugates (ADCs). Co.'s main program is mirvetuximab, an ADC targeting folate receptor alpha, a cell-surface protein overexpressed in a number of epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers. Pivekimab sunirine is an ADC comprised of an antibody designed to target CD123 with site-specific conjugation to a DNA-alkylating payload of the IGN (indolinobenzodiazepine pseudodimer) class. Co.'s pipeline program, IMGC936, is an ADC that is designed to target ADAM9, an enzyme overexpressed in a range of solid tumors and implicated in tumor progression and metastasis. According to our IMGN split history records, Immunogen Inc - Comm has had 0 splits. | |
|
Immunogen Inc - Comm (IMGN) has 0 splits in our IMGN split history database.
Looking at the IMGN split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Immunogen Inc - Comm shares, starting with a $10,000 purchase of IMGN, presented on a split-history-adjusted basis factoring in the complete IMGN split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
03/31/2014 |
|
End date: |
02/12/2024 |
|
Start price/share: |
$14.93 |
|
End price/share: |
$31.23 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
109.18% |
|
Average Annual Total Return: |
7.76% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$20,920.60 |
|
Years: |
9.88 |
|
|
|
|
|